Memantine for Fragile X-associated Tremor/Ataxia Syndrome (FXTAS): A Randomized, Double-Blind, Placebo-Controlled Trial

OBJECTIVE: Memantine, an NMDA receptor uncompetitive antagonist, is currently approved by the Food and Drug Administration for the treatment of moderate to severe Alzheimer’s disease. Anecdotal reports have suggested that memantine may improve neurological and cognitive symptoms of individuals with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Clin Psychiatry
Hauptverfasser: Seritan, Andreea L., Nguyen, Danh V., Mu, Yi, Tassone, Flora, Bourgeois, James A., Schneider, Andrea, Cogswell, Jennifer, Cook, Kylee, Leehey, Maureen, Grigsby, Jim, Olichney, John M., Adams, Patrick, Legg, Wendi, Zhang, Lin, Hagerman, Paul, Hagerman, Randi J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2014
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4296896/
https://ncbi.nlm.nih.gov/pubmed/24345444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4088/JCP.13m08546
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge